TIDMIXI

RNS Number : 4564Z

IXICO plc

12 January 2024

12 January 2024

IXICO plc

("IXICO" or the "Company")

CEO Succession

IXICO plc, (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, announces that Giulio Cerroni has informed the Board of his intention to retire from his role as Chief Executive Officer ("CEO") and director of the Company by the end of 2024 in accordance with his notice period and to ensure a smooth handover of responsibilities. The Board has begun the process to appoint a new CEO in line with its succession plan and will update the market in due course.

For further information please contact:

 
                                                       +44 (0) 20 3763 
 IXICO plc                                              7499 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 
 Cavendish Capital Markets Limited (Nominated          +44 (0) 20 7220 
  Adviser and Sole Broker)                              0500 
 Giles Balleny / Dan Hodkinson (Corporate 
  Finance) 
  Michael F Johnson / Tamar Cranford 
  Smith (Sales)

This announcement contains inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR.

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOADZGMMNMZGDZM

(END) Dow Jones Newswires

January 12, 2024 04:35 ET (09:35 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Ixico Charts.
Ixico (LSE:IXI)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Ixico Charts.